[144] Thermo Fisher Scientific, Inc. SEC Filing

Rhea-AI Filing Summary

Thermo Fisher Scientific (TMO) Form 144 notice for a proposed sale of common stock. The filing shows 385 shares to be sold through Fidelity Brokerage Services with an approximate aggregate market value of $189,661.91 and an approximate sale date of 08/29/2025 on the NYSE. The filing reports 377,612,121 shares outstanding. The securities were listed as acquired on 08/29/2025 by exercise of an option granted 02/26/2019, and payment is indicated as cash. Several identifying fields such as the filer CIK/CCC and the named person for whose account the securities are to be sold are blank in the provided text, and no sales in the past three months are reported.

Positive

• Disclosure filed under Rule 144 indicating compliance with required notice of proposed sale
• Transaction details provided (shares, aggregate value, broker, exchange, acquisition method, payment type)

Negative

• Key identification fields are blank in the provided content (filer CIK/CCC and named person for whose account the sale is to be made), limiting transparency
• Insufficient context on holder status (insider vs non-insider not specified), preventing full assessment of materiality

Insights

Securities Compliance Counsel

TL;DR: Routine Form 144 notice showing a small sale via broker; missing filer identification reduces transparency.

The filing documents a proposed sale of 385 common shares with an aggregate market value of $189,661.91 to be executed on 08/29/2025 through Fidelity on the NYSE. It states acquisition by option exercise (option granted 02/26/2019) and cash payment. The form includes the required seller representation about lacking undisclosed material information. However, key identification fields such as the filer CIK/CCC and the named person for whose account the sale is made are not present in the provided content, which limits confirmatory review and counterparty tracing.

Equity Markets Analyst

TL;DR: Small insider/affiliate sale relative to outstanding shares; unlikely to be market-moving.

The transaction size (385 shares) is immaterial versus reported 377,612,121 shares outstanding, representing a de minimis percentage of float. The report indicates no other sales in the past three months by the same person. From a market-impact perspective this is routine disclosure consistent with Rule 144 notice requirements; absence of seller identity in the provided text prevents linkage to insider status or size of prior holdings.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	385	189661.91	377612121	08/29/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/29/2025	Option Granted 02/26/2019	Issuer			385	08/29/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for TMO report?

The Form 144 reports a proposed sale of 385 common shares of Thermo Fisher (TMO) with an aggregate market value of $189,661.91, to be sold through Fidelity on the NYSE on 08/29/2025.

How were the shares acquired according to the filing?

The filing states the shares were acquired by option exercise; the option was granted on 02/26/2019 and the acquisition date is listed as 08/29/2025.

What payment method is indicated for the purchase of the securities?

Payment for the securities is indicated as cash.

Does the filing show other sales by this person in the past three months?

The filing indicates Nothing to Report for securities sold during the past three months.

How large is the proposed sale relative to shares outstanding?

The filing reports 377,612,121 shares outstanding; the proposed sale of 385 shares is a negligible portion of that total.